Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $423.78 million. The enterprise value is $249.90 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 74.09 million shares outstanding. The number of shares has increased by 68.76% in one year.
| Current Share Class | 74.09M |
| Shares Outstanding | 74.09M |
| Shares Change (YoY) | +68.76% |
| Shares Change (QoQ) | +25.21% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 76.69% |
| Float | 47.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.21, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.21 |
| Quick Ratio | 10.81 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,150.07 |
Financial Efficiency
Return on equity (ROE) is -55.00% and return on invested capital (ROIC) is -35.82%.
| Return on Equity (ROE) | -55.00% |
| Return on Assets (ROA) | -32.86% |
| Return on Invested Capital (ROIC) | -35.82% |
| Return on Capital Employed (ROCE) | -43.38% |
| Weighted Average Cost of Capital (WACC) | 15.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.69M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.75% in the last 52 weeks. The beta is 2.01, so LXEO's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | +82.75% |
| 50-Day Moving Average | 6.65 |
| 200-Day Moving Average | 6.87 |
| Relative Strength Index (RSI) | 40.77 |
| Average Volume (20 Days) | 1,033,698 |
Short Selling Information
The latest short interest is 11.80 million, so 15.92% of the outstanding shares have been sold short.
| Short Interest | 11.80M |
| Short Previous Month | 11.13M |
| Short % of Shares Out | 15.92% |
| Short % of Float | 25.07% |
| Short Ratio (days to cover) | 14.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | -63.80M |
| Operating Income | -109.26M |
| Pretax Income | -99.96M |
| Net Income | -99.96M |
| EBITDA | -108.67M |
| EBIT | -109.26M |
| Earnings Per Share (EPS) | -$1.86 |
Full Income StatementBalance Sheet
The company has $181.77 million in cash and $7.89 million in debt, with a net cash position of $173.88 million or $2.35 per share.
| Cash & Cash Equivalents | 181.77M |
| Total Debt | 7.89M |
| Net Cash | 173.88M |
| Net Cash Per Share | $2.35 |
| Equity (Book Value) | 246.67M |
| Book Value Per Share | 3.38 |
| Working Capital | 171.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$98.56 million and capital expenditures -$397,000, giving a free cash flow of -$98.96 million.
| Operating Cash Flow | -98.56M |
| Capital Expenditures | -397,000 |
| Depreciation & Amortization | 588,000 |
| Net Borrowing | -533,000 |
| Free Cash Flow | -98.96M |
| FCF Per Share | -$1.34 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.76% |
| Shareholder Yield | -68.76% |
| Earnings Yield | -23.59% |
| FCF Yield | -23.35% |
Analyst Forecast
The average price target for LXEO is $18.44, which is 222.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.44 |
| Price Target Difference | 222.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
